- Home
- RNXT vs PMN Comparison
RNXT vs PMN Comparison
Compare RNXT & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- PMN
- Stock Information
- Founded
- RNXT 2012
- PMN 2004
- Country
- RNXT United States
- PMN Canada
- Employees
- RNXT N/A
- PMN N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- RNXT Health Care
- PMN Health Care
- Exchange
- RNXT Nasdaq
- PMN Nasdaq
- Market Cap
- RNXT 31.6M
- PMN 29.8M
- IPO Year
- RNXT 2021
- PMN N/A
- Fundamental
- Price
- RNXT $1.14
- PMN $0.94
- Analyst Decision
- RNXT Strong Buy
- PMN
- Analyst Count
- RNXT 1
- PMN 0
- Target Price
- RNXT $9.00
- PMN N/A
- AVG Volume (30 Days)
- RNXT 195.7K
- PMN 43.3K
- Earning Date
- RNXT 03-31-2025
- PMN 03-31-2025
- Dividend Yield
- RNXT N/A
- PMN N/A
- EPS Growth
- RNXT N/A
- PMN N/A
- EPS
- RNXT N/A
- PMN N/A
- Revenue
- RNXT N/A
- PMN N/A
- Revenue This Year
- RNXT N/A
- PMN N/A
- Revenue Next Year
- RNXT N/A
- PMN N/A
- P/E Ratio
- RNXT N/A
- PMN N/A
- Revenue Growth
- RNXT N/A
- PMN N/A
- 52 Week Low
- RNXT $0.77
- PMN $0.87
- 52 Week High
- RNXT $1.86
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- RNXT 36.31
- PMN 56.16
- Support Level
- RNXT $1.09
- PMN $0.90
- Resistance Level
- RNXT $1.40
- PMN $0.95
- Average True Range (ATR)
- RNXT 0.10
- PMN 0.06
- MACD
- RNXT -0.03
- PMN 0.01
- Stochastic Oscillator
- RNXT 8.51
- PMN 67.79
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.